{
    "organizations": [],
    "uuid": "99c2348cfb7f83b53d2a5eb87b05dd8fd41c8ff9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-and-neurocrine-biosciences/brief-abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-endometriosis-associated-pain-idUSFWN1RN0MF",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10, 2018 / 12:32 PM / Updated 10 minutes ago BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain Reuters Staff 1 Min Read \nApril 10 (Reuters) - Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis : * ASSOCIATED PAIN \n* FDA REQUIRES EXTENDED TIME FOR REVIEW OF ADDITIONAL INFORMATION IN NEW DRUG APPLICATION \n* BASED ON ABBVIEâ€™S REVIEW OF DATA, COMPANY REMAINS CONFIDENT IN NDA AND CONTINUES TO WORK WITH FDA TO BRING ELAGOLIX TO PATIENTS \n* REGULATORY SUBMISSIONS FOR ELAGOLIX IN UTERINE FIBROIDS REMAIN ON TRACK \n* PRESCRIPTION DRUG USER FEE ACT DATE HAS BEEN EXTENDED THREE MONTHS TO Q3 2018 FOR ELAGOLIX Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T15:31:00.000+03:00",
    "crawled": "2018-04-10T15:48:12.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "neurocrine",
        "bioscience",
        "announce",
        "pdufa",
        "target",
        "date",
        "q3",
        "elagolix",
        "endometriosis",
        "associated",
        "pain",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "abbvie",
        "neurocrine",
        "bioscience",
        "announce",
        "pdufa",
        "target",
        "date",
        "q3",
        "elagolix",
        "endometriosis",
        "associated",
        "pain",
        "fda",
        "requires",
        "extended",
        "time",
        "review",
        "additional",
        "information",
        "new",
        "drug",
        "application",
        "based",
        "abbvie",
        "review",
        "data",
        "company",
        "remains",
        "confident",
        "nda",
        "continues",
        "work",
        "fda",
        "bring",
        "elagolix",
        "patient",
        "regulatory",
        "submission",
        "elagolix",
        "uterine",
        "fibroid",
        "remain",
        "track",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "date",
        "extended",
        "three",
        "month",
        "q3",
        "elagolix",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}